NZ592054A - Dengue virus neutralizing antibodies and uses thereof - Google Patents

Dengue virus neutralizing antibodies and uses thereof

Info

Publication number
NZ592054A
NZ592054A NZ592054A NZ59205409A NZ592054A NZ 592054 A NZ592054 A NZ 592054A NZ 592054 A NZ592054 A NZ 592054A NZ 59205409 A NZ59205409 A NZ 59205409A NZ 592054 A NZ592054 A NZ 592054A
Authority
NZ
New Zealand
Prior art keywords
dengue virus
antibodies
antigen binding
binding fragments
neutralizing antibodies
Prior art date
Application number
NZ592054A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of NZ592054A publication Critical patent/NZ592054A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ592054A 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof NZ592054A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10491108P 2008-10-13 2008-10-13
PCT/IB2009/007372 WO2010043977A2 (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ592054A true NZ592054A (en) 2013-06-28

Family

ID=42102977

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592054A NZ592054A (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Country Status (10)

Country Link
US (1) US9073981B2 (enExample)
EP (1) EP2334700B1 (enExample)
JP (2) JP5814790B2 (enExample)
CN (2) CN102272155B (enExample)
AU (1) AU2009305113B2 (enExample)
BR (1) BRPI0914012B1 (enExample)
CA (1) CA2739551C (enExample)
MX (1) MX2011003588A (enExample)
NZ (1) NZ592054A (enExample)
WO (1) WO2010043977A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
EP2651975B1 (en) 2010-12-14 2017-08-09 National University of Singapore Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
SG11201400100SA (en) * 2011-09-09 2014-06-27 Univ Osaka Dengue-virus serotype neutralizing antibodies
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
BR112015013700A8 (pt) * 2012-12-13 2020-02-18 Inovio Pharmaceuticals Inc composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
JP7078350B2 (ja) 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
JP6154126B2 (ja) * 2012-12-20 2017-06-28 功 宮崎 検査キットおよび検査方法
SG11201507359SA (en) * 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
CN103396481B (zh) * 2013-07-18 2015-06-03 华南理工大学 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用
EP3080159A4 (en) * 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
CA3212977A1 (en) 2014-02-11 2015-08-20 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
CA2938495A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
CN107074968B (zh) * 2014-09-01 2021-03-12 国际遗传工程和生物技术中心 疫苗
CN107427566B (zh) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3271390B1 (en) * 2015-03-17 2023-09-27 Agency For Science, Technology And Research A serotype cross-reactive, dengue neutralizing antibody and uses thereof
WO2017011495A1 (en) * 2015-07-14 2017-01-19 Vanderbilt University Engineered antibodies against dengue virus
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
WO2018081754A1 (en) * 2016-10-29 2018-05-03 University Of Miami Anti-zika virus antibodies
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR102238183B1 (ko) 2018-05-04 2021-04-12 가톨릭대학교 산학협력단 유전자 합성을 통해 설계된 뎅기열 바이러스의 유전형 복합 ｎｓ１ 재조합 항원 및 대조군 유행성 플라비바이러스 유전형 복합 ns1 재조합 항원 풀
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
WO2020078568A1 (en) * 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
CN111320688B (zh) * 2018-12-17 2021-08-24 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用
KR102048812B1 (ko) * 2018-12-19 2019-11-26 주식회사 엠디헬스케어 뎅기 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819376A (en) 1956-10-20 1959-09-02 Colne Switchgear K & W Ltd Improvements in electro-magnetic overload units for electrical apparatus
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
CA2894300A1 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
EP2990053A1 (en) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
WO2009011941A2 (en) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region

Also Published As

Publication number Publication date
JP2012504955A (ja) 2012-03-01
EP2334700A2 (en) 2011-06-22
CA2739551A1 (en) 2010-04-22
EP2334700B1 (en) 2017-09-13
CN108610416B (zh) 2022-01-14
BRPI0914012A2 (pt) 2021-02-23
US9073981B2 (en) 2015-07-07
MX2011003588A (es) 2011-10-14
BRPI0914012B1 (pt) 2022-02-15
CN102272155A (zh) 2011-12-07
AU2009305113B2 (en) 2015-07-16
CN108610416A (zh) 2018-10-02
US20120020957A1 (en) 2012-01-26
WO2010043977A2 (en) 2010-04-22
CA2739551C (en) 2019-03-05
JP2016020334A (ja) 2016-02-04
AU2009305113A1 (en) 2010-04-22
JP5814790B2 (ja) 2015-11-17
CN102272155B (zh) 2018-05-25
WO2010043977A3 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
MY150709A (en) Human cytomegalovirus neutralising antibodies and use thereof
UA106771C2 (uk) Моноклональні антитіла до прогастрину та їх використання
UA92505C2 (ru) Композиции на основе антитела против cd3
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
EA201100923A1 (ru) Антитела человека против тканевого фактора
WO2009083009A3 (en) Monoclonal antibodies against cd32b
PH12014502419A1 (en) Specific binding proteins and uses thereof
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
EA201291065A1 (ru) Антитела против vla-4
EA201171237A1 (ru) Антитела к dkk-1
MX2010001237A (es) Nuevos anticuerpos.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 OCT 2016 BY CPAPAYMENTS

Effective date: 20131105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2017 BY PAVIS

Effective date: 20160929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2018 BY PAVIS GMBH

Effective date: 20171002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2019 BY PAVIS GMBH

Effective date: 20181010

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2020 BY PAVIS GMBH

Effective date: 20190920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2021 BY PAVIS PAYMENTS GMBH

Effective date: 20201008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2022 BY PAVIS PAYMENT GMBH

Effective date: 20211005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2023 BY PAVIS PAYMENT GMBH

Effective date: 20221005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230928

LAPS Patent lapsed